Menu Search
Equities

Roivant Sciences Ltd

87S:BER

Roivant Sciences Ltd

Actions
  • Price (EUR)10.77
  • Today's Change0.000 / 0.00%
  • Shares traded--
  • 1 Year change+37.20%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 07:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes product candidates across various therapeutic areas, including immunology, oncology, hematology, and dermatology. Its pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis; mosliciguat, an inhaled soluble sGC activator in development for pulmonary hypertension associated with interstitial lung disease, in addition to other clinical-stage molecules; and namilumab, is a fully human monoclonal antibody targeting granulocyte-macrophage colony stimulating factor, an inflammatory cytokine involved in inflammatory disorders such as sarcoidosis.

  • Revenue in USD (TTM)78.54m
  • Net income in USD4.76bn
  • Incorporated2014
  • Employees845.00
  • Location
    Roivant Sciences Ltd11-12 St. James's SquareSuite 1, 3rd FloorLONDON SW1Y4LBUnited KingdomGBR
  • Phone+44 207 400 3347
  • Websitehttp://roivant.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.